DK1924264T3 - Diaminopyrimidiner som p2x3- og p2x2/3-modulatorer - Google Patents

Diaminopyrimidiner som p2x3- og p2x2/3-modulatorer

Info

Publication number: DK1924264T3
Authority: DK; Denmark
Prior art keywords: diaminopyrimidines; modulators
Prior art date: 2005-09-01

Application number

DK06778331.6T

Other languages

English (en)

Other versions

DK1924264T5 (da

Inventor

David Scott Carter

Michael Patrick Dillon

Anthony P D W Ford

Ronald Charles Hawley

Alam Jahangir

Amy Geraldine Moore

Daniel Warren Parish

Chris Allen Broka

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-09-01

Filing date

2006-08-23

Publication date

2013-10-21

2006-08-23 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2013-10-21 Application granted granted Critical

2013-10-21 Publication of DK1924264T3 publication Critical patent/DK1924264T3/da

2014-03-24 Publication of DK1924264T5 publication Critical patent/DK1924264T5/da

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pulmonology (AREA)
Urology & Nephrology (AREA)
Gastroenterology & Hepatology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

DK06778331.6T 2005-09-01 2006-08-23 Diaminopyrimidiner som P2X3- og P2X2/3-modulatorer DK1924264T5 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US71354805P	2005-09-01	2005-09-01
PCT/EP2006/065606 WO2007025925A1 (en)	2005-09-01	2006-08-23	Diaminopyrimidines as p2x3 and p2x2/3 modulators

Publications (2)

Publication Number	Publication Date
DK1924264T3 true DK1924264T3 (da)	2013-10-21
DK1924264T5 DK1924264T5 (da)	2014-03-24

Family

ID=37492274

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK06778331.6T DK1924264T5 (da)	2005-09-01	2006-08-23	Diaminopyrimidiner som P2X3- og P2X2/3-modulatorer

Country Status (15)

Country	Link
US (7)	US8008313B2 (da)
EP (1)	EP1924264B9 (da)
JP (1)	JP4850914B2 (da)
KR (1)	KR101012926B1 (da)
CN (1)	CN101300012B (da)
AU (1)	AU2006286601B2 (da)
BR (1)	BRPI0615040A2 (da)
CA (1)	CA2620034C (da)
DK (1)	DK1924264T5 (da)
ES (1)	ES2439454T3 (da)
IL (1)	IL189499A (da)
MX (1)	MX2008002733A (da)
PL (1)	PL1924264T3 (da)
SI (1)	SI1924264T1 (da)
WO (1)	WO2007025925A1 (da)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HRP20120901T1 (hr) *	2004-03-05	2012-12-31	F. Hoffmann - La Roche Ag	Diaminopirimidini kao p2x3 i p2x2/3
MY158766A (en) *	2005-04-11	2016-11-15	Xenon Pharmaceuticals Inc	Spiro-oxindole compounds and their uses as therapeutic agents
MY145694A (en) *	2005-04-11	2012-03-30	Xenon Pharmaceuticals Inc	Spiroheterocyclic compounds and their uses as therapeutic agents
NZ565955A (en)	2005-08-22	2011-08-26	Melior Pharmaceuticals I Inc	Methods and formulations for modulating lyn kinase activity and treating related disorders
PL1924264T3 (pl) *	2005-09-01	2014-03-31	Hoffmann La Roche	Diaminopirymidyny jako modulatory P2X<sub>3</sub> I P2X<sub>2/3</sub>
JP4850912B2 (ja) *	2005-09-01	2012-01-11	エフ．ホフマン−ラロシュアーゲー	Ｐ２ｘ３およびｐ３ｘ２／３モジュレーターとしてのジアミノピリミジン
MX2009003257A (es) *	2006-10-04	2009-04-07	Hoffmann La Roche	Procedimiento para la sintesis de derivados de fenoxi diaminopirimidina.
CL2007002953A1 (es) *	2006-10-12	2008-02-01	Xenon Pharmaceuticals Inc	Compuestos derivados de espiro-oxindol; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento del dolor, cancer, prurito, hiperplasia prostatica benigna, hipercolesterolemia.
ATE545416T1 (de)	2006-10-12	2012-03-15	Xenon Pharmaceuticals Inc	Verwendung von spiro-oxindol-verbindungen als therapeutika
WO2008104474A1 (en) *	2007-02-28	2008-09-04	F. Hoffmann-La Roche Ag	Diaminopyrimidines
JP5624762B2 (ja)	2007-03-30	2014-11-12	塩野義製薬株式会社	新規ピロリノン誘導体およびそれを含有する医薬組成物
CA2693809A1 (en) *	2007-07-23	2009-01-29	Melior Discovery, Inc.	Methods of activating irs-1 and akt
JP2011502148A (ja)	2007-10-31	2011-01-20	メルク・シャープ・エンド・ドーム・コーポレイション	疼痛の治療用としてのｐ２ｘ３受容体アンタゴニスト
EP2262766B1 (en)	2008-02-29	2015-11-11	Evotec AG	Amide compounds, compositions and uses thereof
US8552184B2 (en)	2008-07-03	2013-10-08	Melior Pharmaceuticals I, Inc.	Compounds and methods for treating disorders related to glucose metabolism
TW201016702A (en) *	2008-09-25	2010-05-01	Shionogi & Co	Novel pyrrolinone derivative and pharmaceutical composition comprising the same
WO2010045197A1 (en) *	2008-10-17	2010-04-22	Xenon Pharmaceuticals, Inc.	Spiro-oxindole compounds and their use as therapeutic agents
HRP20150882T1 (hr)	2008-10-17	2015-09-25	Xenon Pharmaceuticals Inc.	Spirooksindolski spojevi i njihova upotreba kao terapijska sredstva
CA2741666C (en)	2008-10-31	2017-04-11	Merck Sharp & Dohme Corp.	P2x3, receptor antagonists for treatment of pain
ES2474490T3 (es)	2009-02-13	2014-07-09	Shionogi & Co., Ltd.	Derivados de triazina como antagonistas de receptores P2X3 y/o P2X2/3 y composición farmacéutica que los contiene
US9238647B2 (en)	2009-03-23	2016-01-19	Merck Sharp & Dohme Corp.	P2X3 receptor antagonists for treatment of pain
AU2010229144B2 (en)	2009-03-23	2012-07-12	Merck Sharp & Dohme Corp.	P2X3, receptor antagonists for treatment of pain
AR077252A1 (es)	2009-06-29	2011-08-10	Xenon Pharmaceuticals Inc	Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
MY165579A (en)	2009-10-14	2018-04-05	Xenon Pharmaceuticals Inc	Synthetic methods for spiro-oxindole compounds
US20110086899A1 (en) *	2009-10-14	2011-04-14	Xenon Pharmaceuticals Inc.	Pharmaceutical compositions for oral administration
JP2013521232A (ja)	2010-02-26	2013-06-10	ゼノン・ファーマシューティカルズ・インコーポレイテッド	局所投与のためのスピロオキシインドール化合物の医薬組成物および治療剤としてのその使用
US20130158055A1 (en)	2010-05-28	2013-06-20	Andrew G. Reaume	Prevention Of Pancreatic Beta Cell Degeneration
RU2565073C2 (ru)	2010-08-10	2015-10-20	Сионоги Энд Ко., Лтд.	Триазиновое производное и включающая его фармацевтическая композиция, обладающая анальгетической активностью
WO2012020742A1 (ja)	2010-08-10	2012-02-16	塩野義製薬株式会社	新規複素環誘導体およびそれらを含有する医薬組成物
US9550763B2 (en)	2012-02-09	2017-01-24	Shionogi & Co., Ltd.	Heterocyclic ring and carbocyclic derivative
HK1205113A1 (en)	2012-04-12	2015-12-11	Xenon Pharmaceuticals Inc.	Asymmetric syntheses for spiro-oxindole compounds useful as therapeutic agents
TWI637949B (zh)	2013-06-14	2018-10-11	塩野義製藥股份有限公司	胺基三衍生物及含有其等之醫藥組合物
KR102196885B1 (ko) *	2013-08-23	2020-12-30	애퍼런트 파마슈티컬스 인크.	급성, 아급성 또는 만성 기침의 치료를 위한 디아미노피리미딘 p2x3 및 p2x2/3 수용체 조절제
EP3981406A1 (en)	2014-07-03	2022-04-13	Afferent Pharmaceuticals Inc.	Methods and compositions for treating diseases and conditions
CN104447574A (zh) *	2014-12-26	2015-03-25	苏州步跃医药科技有限公司	一种奥美普林的合成方法
TW201636017A (zh)	2015-02-05	2016-10-16	梯瓦製藥國際有限責任公司	以螺吲哚酮化合物之局部調配物治療帶狀疱疹後遺神經痛之方法
US11260056B2 (en) *	2015-09-29	2022-03-01	Afferent Pharmaceuticals, Inc.	Diaminopyrimidine P2X3 and P2X2/3 receptor modulators for use in the treatment of cough
AU2017233841B9 (en) *	2016-03-14	2021-09-09	Afferent Pharmaceuticals Inc.	Pyrimidines and variants thereof, and uses therefor
CA3018180C (en)	2016-03-25	2024-02-20	Ronald Charles Hawley	Pyrimidines and variants thereof, and uses therefor
WO2017218920A1 (en)	2016-06-16	2017-12-21	Teva Pharmaceuticals International Gmbh	Asymmetric synthesis of funapide
MX381790B (es) *	2016-12-20	2025-03-13	Afferent Pharmaceuticals Inc	Sales cristalinas y polimorfos de un antagonista de p2x3.
KR102634575B1 (ko)	2017-04-10	2024-02-06	멜리어 파마슈티칼스 아이, 인코포레이티드	지방세포의 처리
CN109761910B (zh) *	2018-12-04	2021-11-19	华中农业大学	一种艾地普林的合成方法
MA56020A (fr) *	2019-05-31	2022-04-06	Chiesi Farm Spa	Dérivés de pyridopyrimidines utilisés en tant qu'inhibiteurs de p2x3
MA56022A (fr)	2019-05-31	2022-04-06	Chiesi Farm Spa	Dérivés d'amino quinazoline servant d'inhibiteurs de p2x3
KR20220016909A (ko) *	2019-06-06	2022-02-10	베이징 타이드 파마슈티컬 코퍼레이션 리미티드	P2x3 및/또는 p2x2/3 수용체 길항제, 이를 함유하는 약학적 조성물 및 이의 용도
AU2020390377B2 (en) *	2019-11-29	2023-12-21	Wuhan Ll Science And Technology Development Co., Ltd.	Compound containing benzene ring and application thereof
US11607395B2 (en) *	2019-12-18	2023-03-21	Curasen Therapeutics, Inc.	Methods for improving neurological diseases and disorders
TWI849314B (zh) *	2020-06-01	2024-07-21	日商住友化學股份有限公司	化合物、樹脂、抗蝕劑組成物及抗蝕劑圖案的製造方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5874420A (en)	1995-12-26	1999-02-23	Allegheny University Of The Health Sciences	Process for regulating vagal tone
SE9701304D0 (sv) *	1997-04-09	1997-04-09	Astra Pharma Prod	Compounds
US6583148B1 (en) *	1999-04-08	2003-06-24	Krenitsky Pharmaceuticals, Inc.	Neurotrophic substituted pyrimidines
AU2002343644A2 (en)	2001-11-09	2003-05-19	Algos Therapeutics, Inc.	Antisense modulation of purinoreceptor P2X3
HRP20120901T1 (hr)	2004-03-05	2012-12-31	F. Hoffmann - La Roche Ag	Diaminopirimidini kao p2x3 i p2x2/3
AU2005266887B2 (en) *	2004-07-22	2011-08-18	Duska Scientific Co.	Method of diagnosing, monitoring and treating pulmonary diseases
JP4850912B2 (ja) *	2005-09-01	2012-01-11	エフ．ホフマン−ラロシュアーゲー	Ｐ２ｘ３およびｐ３ｘ２／３モジュレーターとしてのジアミノピリミジン
WO2007025901A1 (en) *	2005-09-01	2007-03-08	F. Hoffmann-La Roche Ag	Diaminopyrimidines as p2x3 and p2x2/3 modulators
PL1924264T3 (pl) *	2005-09-01	2014-03-31	Hoffmann La Roche	Diaminopirymidyny jako modulatory P2X<sub>3</sub> I P2X<sub>2/3</sub>
CA2619919C (en) *	2005-09-01	2014-04-01	F. Hoffmann-La Roche Ag	Diaminopyrimidines as p2x3 and p2x2/3 modulators

2006
- 2006-08-23 PL PL06778331T patent/PL1924264T3/pl unknown
- 2006-08-23 WO PCT/EP2006/065606 patent/WO2007025925A1/en not_active Ceased
- 2006-08-23 SI SI200631683T patent/SI1924264T1/sl unknown
- 2006-08-23 AU AU2006286601A patent/AU2006286601B2/en active Active
- 2006-08-23 CN CN2006800405247A patent/CN101300012B/zh active Active
- 2006-08-23 KR KR1020087007681A patent/KR101012926B1/ko active Active
- 2006-08-23 CA CA2620034A patent/CA2620034C/en active Active
- 2006-08-23 DK DK06778331.6T patent/DK1924264T5/da active
- 2006-08-23 BR BRPI0615040-3A patent/BRPI0615040A2/pt not_active Application Discontinuation
- 2006-08-23 JP JP2008528482A patent/JP4850914B2/ja active Active
- 2006-08-23 EP EP06778331.6A patent/EP1924264B9/en active Active
- 2006-08-23 MX MX2008002733A patent/MX2008002733A/es active IP Right Grant
- 2006-08-23 ES ES06778331.6T patent/ES2439454T3/es active Active
- 2006-08-25 US US11/509,921 patent/US8008313B2/en active Active
2008
- 2008-02-13 IL IL189499A patent/IL189499A/en active IP Right Grant
2011
- 2011-07-19 US US13/186,078 patent/US8524725B2/en active Active
2013
- 2013-04-19 US US13/866,212 patent/US20130225570A1/en not_active Abandoned
2016
- 2016-06-01 US US15/170,666 patent/US20160271131A1/en not_active Abandoned
2018
- 2018-07-05 US US16/028,365 patent/US20180311240A1/en not_active Abandoned
2020
- 2020-09-25 US US17/032,489 patent/US20210008071A1/en not_active Abandoned
2024
- 2024-07-22 US US18/779,395 patent/US20250025462A1/en active Pending

Also Published As

Publication number	Publication date
US20120122859A1 (en)	2012-05-17
US8524725B2 (en)	2013-09-03
US20210008071A1 (en)	2021-01-14
AU2006286601A1 (en)	2007-03-08
IL189499A (en)	2013-05-30
EP1924264A1 (en)	2008-05-28
EP1924264B9 (en)	2014-02-19
ES2439454T3 (es)	2014-01-23
US20160271131A1 (en)	2016-09-22
CN101300012A (zh)	2008-11-05
KR101012926B1 (ko)	2011-02-09
DK1924264T5 (da)	2014-03-24
BRPI0615040A2 (pt)	2011-04-26
JP4850914B2 (ja)	2012-01-11
US20180311240A1 (en)	2018-11-01
US20070049609A1 (en)	2007-03-01
WO2007025925A1 (en)	2007-03-08
CA2620034A1 (en)	2007-03-08
JP2009507000A (ja)	2009-02-19
SI1924264T1 (sl)	2013-12-31
KR20080049802A (ko)	2008-06-04
US20130225570A1 (en)	2013-08-29
US20250025462A1 (en)	2025-01-23
PL1924264T3 (pl)	2014-03-31
ES2439454T9 (es)	2014-03-07
US8008313B2 (en)	2011-08-30
CA2620034C (en)	2013-10-01
AU2006286601B2 (en)	2012-07-05
MX2008002733A (es)	2008-03-26
IL189499A0 (en)	2008-08-07
EP1924264B1 (en)	2013-09-18
CN101300012B (zh)	2011-09-14

Publication	Publication Date	Title
DK1924264T3 (da)	2013-10-21	Diaminopyrimidiner som p2x3- og p2x2/3-modulatorer
HUS2400005I1 (hu)	2024-04-28	Diaminopirimidinek mint P2X3 és P2X2/3 antagonisták
IL189500A0 (en)	2008-08-07	Diaminopyrimidines as p2x3 and p3x2/3 modulators
DK1902037T3 (da)	2009-12-21	2,4-diamino-pyrimidiner som auroainhibitorer
DE602006017579D1 (de)	2010-11-25	Klebstoff für optischen film sowie von dem klebstoff gebrauch machendes klebevlies und optisches glied
DE502006006338D1 (de)	2010-04-15	Ächen
DE502006002243D1 (de)	2009-01-15	Projektionsanzeige
DE502006007885D1 (de)	2010-10-28	Kontrasterhöhender rückprojektionsschirm
DE602006015807D1 (de)	2010-09-09	Abgeschwächter dengue-serotyp-2-stamm
ATE537171T1 (de)	2011-12-15	Aryl-isoxazol-4-yl-imidazoä1,5-aüpyridin-deriva e
EP1915162A4 (en)	2009-08-26	Modulators
DE602006018502D1 (de)	2011-01-05	Ng
EP1848438A4 (en)	2010-09-01	DIAMINOPHENOTHIAZINE COMPOSITIONS AND THEIR USE
ITMI20050071A1 (it)	2006-07-22	Schermo di proiezione
FIU20050276U0 (fi)	2005-08-26	Kiinnityslaite
EP1898316A4 (en)	2012-04-04	CLIENT DEVICE
FR2888926B1 (fr)	2007-09-28	Interferometre ewod
NO20052429D0 (no)	2005-05-20	Konstrastmidler
FR2890387B1 (fr)	2009-08-07	Composant micromecanique
FR2883302B3 (fr)	2007-06-08	Textile-ecran anti-allergenes
FI6726U1 (fi)	2005-06-28	Hieromalaite
NL2000179A1 (nl)	2007-02-26	Projectiescherm.
EP1940415A4 (en)	2010-03-17	19,23,24,25,26,27-HEXANOR-1ALPHA-HYDROXYVITAMINE D3
ITBO20050041U1 (it)	2007-01-13	Elettroemanatore di sostanze volatili nell'ambiente
FI20051214A0 (fi)	2005-11-28	Kello-laskin